Business Context and Reporting Period
This Form 8-K Current Report was filed by Protagonist Therapeutics, Inc. on December 14, 2017, covering events that occurred on December 12, 2017. The company is a Delaware corporation and an emerging growth company. The filing addresses changes to the Board of Directors and associated compensatory arrangements.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and director compensation rather than operational financial performance.
Material Changes
- Resignation: Julie Papanek Grant resigned from the Board of Directors, as well as the Audit and Compensation Committees, effective December 12, 2017. The resignation was not due to any disagreement with the Company.
- Appointments: Sarah Noonberg was appointed as a Class I director to fill the vacancy, serving until the 2020 annual meeting. She was designated as an independent director and appointed to the Audit Committee.
- Committee Adjustment: Lewis T. "Rusty" Williams, M.D., Ph.D., was appointed to the Compensation Committee to fill the vacancy created by Ms. Grant's resignation.
Compensatory Arrangements and Outlook
Dr. Noonberg's compensation package includes the following standard arrangements for non-employee directors:
- Cash Fees: $40,000 annual fee for Board service and $7,500 annual fee for Audit Committee service.
- Initial Stock Option Grant: 24,000 shares granted on December 15, 2017, at fair market value. Vesting occurs in equal monthly installments over three years, subject to continuous service, with full acceleration upon a change in control.
- Annual Stock Option Grant: 12,000 shares granted at each annual meeting of stockholders at fair market value. Vesting occurs at the earlier of one year or the next annual meeting, subject to continuous service, with full acceleration upon a change in control.
- Indemnification: Dr. Noonberg will enter into the Company's standard indemnification agreement.
The filing contains no forward-looking guidance, risk factors, or contingencies beyond the standard terms of the director appointment.
Investor Verification Checklist
- Verify the independence status of Dr. Sarah Noonberg under Nasdaq listing standards.
- Confirm the fair market value of the stock on December 15, 2017, to determine the exercise price of the initial 24,000 share option grant.
- Review the Company's proxy statement for the 2020 annual meeting to confirm the expiration of Dr. Noonberg's Class I director term.
- Check for any subsequent filings regarding the vesting schedule or acceleration triggers related to a potential change in control.